Reduction of anti-malarial consumption after rapid diagnostic tests implementation in Dar es Salaam: a before-after and cluster randomized controlled study. by D'Acremont, V. et al.
Reduction of anti-malarial consumption after rapid
diagnostic tests implementation in Dar es Salaam: a
before-after and cluster randomized controlled study
D'Acremont et al.
D'Acremont et al. Malaria Journal 2011, 10:107
http://www.malariajournal.com/content/10/1/107 (29 April 2011)
RESEARCH Open Access
Reduction of anti-malarial consumption after
rapid diagnostic tests implementation in Dar es
Salaam: a before-after and cluster randomized
controlled study
Valérie D’Acremont1,2,3*, Judith Kahama-Maro1,2,3, Ndeniria Swai3, Deo Mtasiwa4, Blaise Genton1,2,5 and
Christian Lengeler1,2
Abstract
Background: Presumptive treatment of all febrile patients with anti-malarials leads to massive over-treatment. The
aim was to assess the effect of implementing malaria rapid diagnostic tests (mRDTs) on prescription of anti-
malarials in urban Tanzania.
Methods: The design was a prospective collection of routine statistics from ledger books and cross-sectional
surveys before and after intervention in randomly selected health facilities (HF) in Dar es Salaam, Tanzania. The
participants were all clinicians and their patients in the above health facilities. The intervention consisted of training
and introduction of mRDTs in all three hospitals and in six HF. Three HF without mRDTs were selected as matched
controls. The use of routine mRDT and treatment upon result was advised for all patients complaining of fever,
including children under five years of age. The main outcome measures were: (1) anti-malarial consumption
recorded from routine statistics in ledger books of all HF before and after intervention; (2) anti-malarial prescription
recorded during observed consultations in cross-sectional surveys conducted in all HF before and 18 months after
mRDT implementation.
Results: Based on routine statistics, the amount of artemether-lumefantrine blisters used post-intervention was
reduced by 68% (95%CI 57-80) in intervention and 32% (9-54) in control HF. For quinine vials, the reduction was
63% (54-72) in intervention and an increase of 2.49 times (1.62-3.35) in control HF. Before-and-after cross-sectional
surveys showed a similar decrease from 75% to 20% in the proportion of patients receiving anti-malarial treatment
(Risk ratio 0.23, 95%CI 0.20-0.26). The cluster randomized analysis showed a considerable difference of anti-malarial
prescription between intervention HF (22%) and control HF (60%) (Risk ratio 0.30, 95%CI 0.14-0.70). Adherence to
test result was excellent since only 7% of negative patients received an anti-malarial. However, antibiotic
prescription increased from 49% before to 72% after intervention (Risk ratio 1.47, 95%CI 1.37-1.59).
Conclusions: Programmatic implementation of mRDTs in a moderately endemic area reduced drastically over-
treatment with anti-malarials. Properly trained clinicians with adequate support complied with the
recommendation of not treating patients with negative results. Implementation of mRDT should be integrated
hand-in-hand with training on the management of other causes of fever to prevent irrational use of antibiotics.
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Background
One essential component of the global malaria control
strategy is prompt diagnosis and treatment (within 24
hours of onset of illness) with an effective drug [1].
Because of the scarce availability of laboratory facilities
and the high mortality of malaria in young children,
presumptive treatment in case of fever was seen as the
only practical solution to improve child survival. This
strategy thus became part of the Integrated Management
of Childhood Illness (IMCI) decision chart. The strategy
of presumptive treatment was easily and rapidly adopted
by health workers to such an extent that it started also
to be applied beyond the initial high-risk group: 1) to
children older than five years and even adults; 2) in low
endemicity areas; and 3) in setting where laboratory
diagnosis was actually available [2]. This led to a situa-
tion in which the principle of proper diagnosis prior to
treatment became an exception rather than the rule.
Whatever the medical history (when taken) and irre-
spective of the clinical examination (if done at all), the
same treatment is prescribed: an anti-malarial drug, pos-
sibly supplemented by an antipyretic. When the patient
returns with persistent fever a second-line anti-malarial
drug is given, sometimes intravenously. This may go on
until either the spontaneous recovery of the patient
from his/her (often viral) illness or up to a deterioration
of the patient’s condition due to an unrecognized bac-
terial infection. The strategy of presumptive treatment
of all fevers with anti-malarials leads clinicians to believe
that all fevers are due to malaria, resulting in a massive
over-diagnosis [3,4], and more importantly to ignoring
non-malaria causes of fever that have similar, or even
higher case fatality rates than malaria [5,6].
The availability of reliable, easy-to-use and affordable
malaria rapid diagnostic tests (mRDTs) allows now a
realistic switch from presumptive treatment to labora-
tory-confirmed diagnosis and treatment upon result [7].
This is especially important considering the trend of
malaria decline in Africa, which leads to a strong reduc-
tion in the proportion of fevers due to malaria [8].
There is general agreement that diagnosis should be
part of fever case management and WHO has just chan-
ged its recommendation from presumptive to labora-
tory-based diagnosis and treatment upon result [9].
Hence, the discussion is now no more on whether
laboratory diagnosis for malaria should be deployed
[10], but on how best to implement it. Zambia was the
first sub-Saharan country to deploy mRDT at the
national scale in 2004 followed by Senegal in 2006.
Since then, several countries have adopted laboratory-
confirmed diagnosis, even in highly endemic areas.
However, the implementation of mRDT at scale poses
many challenges. Rigorous procedures to train and
supervise clinicians, to strengthen procurement systems
and to ensure quality assurance need to be established.
Strong monitoring and evaluation plans need to be put
in place. The impact of large-scale implementation of
mRDT needs to be carefully assessed in different set-
tings and health systems to ensure that it actually
reduces over-diagnosis, wastage of anti-malarial drugs
and prevents patient suffering.
In order to evaluate the impact of mRDT implementa-
tion on anti-malarial use and fever case management, a
large study was conducted under near-programme con-
ditions in Dar es Salaam, the main urban setting of Tan-
zania with low to moderate malaria endemicity. The
primary objective was to measure the change in overall
anti-malarial consumption at different levels of the
health system. Secondary objectives were to assess the
effect of mRDT implementation on the number and
type of patients tested and/or treated for malaria, the
number of non-malaria laboratory tests performed and
the number of antibiotic prescriptions. Health outcomes
were not considered since the safety of withholding
anti-malarials in febrile children with a negative result
for a rapid test was the subject of a rigorous separate
assessment published elsewhere [11]. To ensure robust-
ness in the findings, data were collected from two inde-
pendent sources and effects of mRDT implementation
evaluated with three different study designs, including a
cluster randomized controlled analysis. Introducing
mRDT represents a new approach to managing patients,
and requires thus clinicians’ behaviour change. The
health facility was therefore used as allocation and ran-
domization unit and not the patient as in previous stu-
dies [12-14].
Methods
Study setting and population
The study took place from January 2006 to September
2008 in Dar es Salaam, the economic capital of Tanza-
nia, with an estimated population of over 3,000,000
inhabitants. The level of malaria endemicity has been
rather low since at least 2003 [15], with an entomologi-
cal inoculation rate of 1.3 and a parasite prevalence in
the general population of 7% in 2007 [16]. Transmission
is perennial with peaks during the main rainy season,
which lasts from March to May. Dar es Salaam has
three municipalities with a public health system orga-
nized in three levels (district hospital, health centres and
dispensaries). All three district hospitals (Mwananya-
mala, Amana and Temeke hospitals) were included. In
each municipality a trio of similar HC/D (nine in total)
was created on the basis of the following criteria: avail-
ability of microscopy, accuracy of the general registers
(called MTUHA books) and laboratory registers, socio-
economic status of the catchment population, quality of
governance of the health facility (HF) and willingness of
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the staff to participate. One HC/D in each trio was then
randomly assigned to be the control HF. There were
thus six intervention HF (two HC/D per municipality)
and three control HF (one HC/D per municipality); the
intervention was also implemented in the three hospitals
but for which no control could obviously be found
(Figure 1).
Intervention
In February 2007, after a sensitization meeting with the
persons in charge of the nine intervention HF, the City
Medical Officer of Health (JKM, who was also one of
the investigators) and representatives of the Municipal
Medical Offices of Health, five one-day training sessions
were organized and attended by a total of 116 clinicians,
31 laboratory technicians, 31 nurses and three pharma-
cists. The training included one hour on the situation of
malaria in Tanzania, half an hour on malaria diagnosis
in Africa and in Dar es Salaam, one hour on the clinical
use of each type of malaria tests, one hour practical in
which participants performed a mRDT on each other,
and finally two hours of group work on five clinical case
studies. The guidelines for the use of mRDTs were the
following: 1) only patients complaining of fever should
be tested; 2) no anti-malarials should be prescribed
when the result of the mRDT is negative, regardless of
the age of the patient; 3) for non-malaria problems,
IMCI guidelines should be followed in children under
five years.
Investigators then went to each HF to discuss mRDT
implementation using a standard check-list to be filled
in by the focal person for mRDT. Between mid- and
end of March 2007, the first consignment of mRDTs
was brought to each HF and a supervision visit con-
ducted 3 days later. Thereafter, supervision took place 1,
2, 5, 10 and 15 months after mRDT introduction. Speci-
fic problems in 4 HF were addressed by one or two
additional on-site meetings. Importantly no incentives
were given to any health worker. Control HF were given
mRDTs after 18 months (November 2008), after a simi-
lar training of their clinical staff.
Project design
In order to come to robust conclusions data were col-
lected with two complementary tools, and outcomes
assessed with three different designs (Figure 1).
Pre-intervention survey
in 9 intervention HF
937 consultations observed
Post-intervention survey
in 9 intervention HF
954 consultations observed
2007 20082006
Pre-intervention survey
in 3 matched control HF
307 consultations observed
Post-intervention survey
in 3 matched control HF
330 consultations observed
Jan
among which 6 matched HF
637 consultations observed
among which 6 matched HF
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2b. Cluster randomized study
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Figure 1 Study methodology with 3 different evaluation methods: (1) longitudinal routine statistics collection, (2a) repeated cross-sectional
surveys on consultations processes with a before-and-after comparison and (2b) cluster randomized controlled comparison of consultation
processes. HF = Health facilities.
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Data collection tool 1: routine statistics from ledger books
A longitudinal study based on the continuous monitor-
ing of routine statistics (MTUHA books) was conducted
in intervention and control HF for a period of 15
months before (including one long and one short rainy
season) and 18 months after mRDT implementation
(including two long and one short rainy seasons). All
MTUHA books from the years 2006 to 2008 were col-
lected to get monthly information on the following:
number of new attendances, number of specific diag-
noses, number of laboratory tests, number of malaria
tests and their results. The number of anti-malarials and
antibiotics consumed per month per health facility were
collected from ledger books in the main stores. To get
the monthly consumption for each drug, the total num-
ber of tablets, vials or blisters (for artemether/lumefan-
trine - ALu) issued by the main store to the different
departments of the HF was counted, excluding the
drugs issued to another HF. To get the monthly number
of ALu dispensed to patients, the number of patients
receiving one of the four types of blisters was counted
from the books used at the dispensing windows.
Data collection tool 2: cross-sectional surveys of
consultation processes
Two cross-sectional surveys were also conducted, one
that took place 2-5 months before and the other 15-18
months after mRDT implementation in the nine inter-
vention and three control HF (Figure 1). In each HF,
100 consultations were observed at the Outpatient
Department by a person (clinical officer or nurse) that
was independent from the health facility and from the
research team and did not know what the primary out-
come of the study was. In order to lessen the influence
of season, 50 consecutive consultations were observed in
each HF in a first week and an additional 50 consulta-
tions were observed 6 weeks later. The targeted sample
size for each of the two surveys (before and after) was
thus 1,200 consultations. The sample size of 600
patients in the intervention and 300 patients in the con-
trol primary care HF was not calculated to detect a sig-
nificant difference on the primary outcome since the
effect of the introduction of mRDT on anti-malarial pre-
scription was expected to be considerable and hence the
sample size needed very small. But a small sample size
would have precluded assessing with sufficient confi-
dence the effect of mRDT introduction on other out-
comes of interest. Hence, the sample size was calculated
to allow the detection of a 20% difference in secondary
outcomes, i.e. proportion of patients tested and propor-
tion of patients prescribed antibiotics (assumed to be
both 50% in the intervention group) with a power of
80% and a significance level of 0.05.
The inclusion criteria for attending patients (of any
age) were: 1) first consultation for the present problem;
2) absence of severe illness requiring immediate admis-
sion or referral; 3) main complaint not being an injury
or trauma. As clinicians in Dar es Salaam (and in most
places in Africa) tend to consider the diagnosis of
malaria even in the absence of fever [2], fever/history of
fever was not used as an inclusion criteria, in order to
get the full range of situations in which malaria is diag-
nosed or treated and thus to compare realistically the
results of the cross-sectional surveys with the routine
statistics. A standardized questionnaire in Swahili lan-
guage was used by the observers while following the
consultation process.
A first consent to participate was requested from the
observed clinician after explaining him/her the aims of
the study and the conditions of observation (confidenti-
ality, anonymity and no interference). Informed consent
was then requested by the observed clinician from each
of his/her patients. The following were observed: com-
plaints mentioned spontaneously by the patient, ques-
tions asked by the clinician and the corresponding
answers by the patient, signs looked for and laboratory
tests ordered by the clinician, tests results, diagnoses,
drugs and advice given by the clinician.
This cross-sectional information was analyzed using
two designs: (1) comparing anti-malarial prescriptions
between pre-intervention and 18 months post-interven-
tion surveys in the nine intervention health facilities
(thereafter called before-and-after analysis) and (2) com-
paring anti-malarial prescriptions between six interven-
tion and their three matched controls
contemporaneously, during the post-intervention survey
(cluster randomized analysis) (Figure 1).
Statistical analyses
For the routine statistics data, the unit of analysis was
the HF rather than the patient, in order to give the
same weight to each HF. Linear models were fitted to
the monthly number of anti-malarial or antibiotic doses
issued and the number of performed diagnostic tests,
and results were expressed as a percentage of the pre-
intervention mean. Random effects allowed accounting
for differences between health facilities. The results were
finally expressed as the ratio of numbers post- over pre-
intervention (PP ratio). From this, the percentage reduc-
tions could be calculated as (1-PP) * 100. For drug vari-
ables, 95% confidence intervals (CI) could not be
calculated for the individual HF because of the auto-cor-
related structure of the data, reflecting month-to-month
variations in issuing of drugs. For instance, when large
drug volumes were issued from the main store on a cer-
tain month, there could be a compensatory reduction
the next month. Data were entered in Microsoft Excel
2002 and analysed using the STATA version 10 xtreg
command.
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For the cross-sectional studies (before-and-after and
cluster randomized analyses), the unit of analysis was
the patient. All patients observed were included in the
study population analysis. Since the number of consulta-
tions observed in each facility was almost the same, the
weight given to each HF was almost identical and this
allowed a direct comparison with the longitudinal study.
Comparison of proportions was done by calculating
odds ratios using a multilevel mixed-effects logistic
regression model to account for clustering. Risk ratios
(RR) were calculated from the fitted values for each cell
of the 2 by 2 tables. P-values (2-sided) were calculated
using Pearson א2 statistics. Data were entered in Epi
Info version 3.5.1 and analyzed in STATA version 10.
The level of agreement between results given by the
two different sources of data (the routine statistics and
the repeated cross-sectional surveys) was measured by
the Lin concordance-correlation coefficient [17].
Results
Routine statistics from ledger books - longitudinal study
Nearly all required data could be retrieved from the
MTUHA books with a few exceptions: among a total of
3,960 monthly data points to be collected (10 variables
measured in 12 HF during 33 months), only 36 were
missing. For the monthly drug quantification, missing
data were replaced by the mean of all data of the corre-
sponding pre- or post-intervention period. Missing
monthly numbers of consultations were replaced by the
mean of the value from the month before and the
month after.
Impact of mRDT implementation on anti-malarial
consumption
The number of ALu blisters issued by the main store of
the 9 intervention HF decreased from a total of 20’660
per month to 7’933 per month after mRDT implementa-
tion. It decreased in each of the 9 HF with PP ratios
ranging from 0.04 to 0.63 (Table 1). When using HF as
a unit, the overall PP ratio was 0.32 (95% CI 0.20-0.43)
corresponding to an overall decrease of 68%. The impact
of mRDT was stronger in dispensaries than in health
centres or hospitals (PP ratio 0.26 versus 0.35 and 0.34).
There was also a clear trend when analysing the data by
municipality (PP ratios 0.32, 0.22 and 0.41 for Munici-
pality 1, 2 and 3 respectively). When only looking at the
last six months of the study to assess the sustainability
of mRDT implementation the results were even better
(PP ratio 0.25, 95% CI 0.13-0.37). In the three control
HF, the overall PP ratio using the whole period was 0.68
(95% CI 0.46-0.91) (Table 1).
Figure 2 shows the monthly consumption of ALu over
time, with the contribution of each HF. The four weight
categories of ALu blisters were included, with one blis-
ter counting as one anti-malarial treatment course.
There was a marked decrease in ALu consumption just
after mRDT initiation and then a further decrease four
months later. The initial four months of the intervention
period was used to identify and rectify operational pro-
blems (use of microscopy instead of mRDT, lack of trust
in laboratory technicians, conflict of interest with private
laboratories, and reshuffle of staff) in the four HF where
little impact was observed during the first four months.
A similar reduction of injectable quinine consumption
was found in each of the nine intervention HF (average
PP ratio 0.37, 95% CI 0.28-0.46) (Table 1). For quinine
there was also a longer period of observation before
mRDT initiation (15 months) compared to ALu which
was only introduced in the country in January 2007. In
the three control HF, there was a marked increase in
quinine use over the same period (PP ratio 2.49, 95% CI
1.62-3.35).
Table 1 shows that in some HF, the number of issued
ALu blisters was much higher than the actual number
of positive patients (median excess: 168%). These
amounts represent the quantities ‘consumed’ by the HF
and not necessarily the numbers of blisters received by
patients. When looking at data from dispensing books
after mRDT implementation, this excess of quantities
consumed over quantities dispensed was confirmed
(median excess: 145%). “Mishandling” of drug stocks is
likely to be the main reason for the over-consumption
of anti-malarials after mRDT implementation (although
at a much lower level than before).
Impact of mRDT implementation on malaria testing
In the nine intervention HF, from January 2006 to March
2007 (before mRDT initiation) a total of 20,143 blood
slides were performed on average per month. After mRDT
initiation, 27,398 mRDTs and 768 blood slides were per-
formed on average per month (Figure 3). Although this
was not formally recommended during training, micro-
scopy was almost entirely replaced by mRDT as first-line
malaria test, except for a few special cases (admitted
patients, persisting fever in outpatients with malaria, dur-
ing short periods of mRDT stock out). The number of
patients attending the nine intervention HF for a new con-
sultation increased slightly over time (61’642 before and
68’065 after mRDT implementation on average per
month). The proportion of patients tested for malaria
increased in all health facilities except 2, from a median of
30% to 42% (PP ratio 1.21) when mRDTs were introduced,
and thereafter the proportion of patients tested was stable
up to the end of the project (Figure 3).
Impact of mRDT implementation on diagnoses
The total number of patients with a diagnosis of
“malaria” given by the clinicians was 27,693 per month
before and 9,920 after mRDT initiation. This represents
a three-fold decrease (PP ratio 0.33, 95% CI 0.28-0.38)
(Figure 3). By contrast, for the diagnoses of acute
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respiratory infection, pneumonia, diarrhoeal diseases and
urinary tract infections there was no change or even an
increase after mRDT implementation (PP ratio 1.02,
1.29, 1.15, 1.46, respectively). The number of “ill defined
syndrome” as well as of “other diagnoses” increased
much more (PP ratios 2.14 and 2.36, respectively). In
the three control HF, there was no change in the num-
ber of patients with a diagnosis of malaria (PP ratio
1.03, 95% CI 0.82-1.24), while acute respiratory infec-
tions, pneumonia, diarrhoeal diseases and urinary tract
infections increased after mRDT implementation (PP
ratio 1.59, 1.30, 1.55 and 2.12, respectively).
Impact of mRDT implementation on malaria positivity rate
At the time of microscopy, the positivity rate of the rou-
tine malaria tests in the nine HF was very high: 49%
(range 13 - 88%) and it was similar in the three types of
HF: 43% in hospitals, 60% in health centres and 57% in
dispensaries. After intervention, the positivity rate of rou-
tine mRDTs was only 8% (range 6 - 12%)(Figure 3), which
is in line with what had been shown in previous studies
using expert microscopy in Dar es Salaam [15]. The per-
formance of routine mRDTs evaluated in one health cen-
tre was excellent (97% sensitivity, 97% specificity) [18].
Impact of mRDT implementation on antibiotics
consumption
The total consumption of oral antibiotics did not change
after mRDT implementation (PP ratio 1.02, 95% CI
0.92-1.13). In control HF, the total consumption of all
oral antibiotics increased a bit more (PP ratio 1.26, 95%
CI 1.00-1.52) than in the intervention HF (PP ratio 1.14,
Table 1 Routine statistics of ledger books: average monthly number of patients positive by mRDT, and ALu blisters &
quinine vials issued by the main store, before and after mRDT implementation, in intervention and control health
facilities
Health
facility
Patients positive
by mRDT
Number per
monthn
ALu blisters £ Quinine vials &
Before mRDT
initiation*
Blisters per
month
n
After mRDT
initiation#
Blistersper
month
n
Post-intervention
blisters
as a proportion
of
pre-intervention
PP (95% CI)
Before mRDT
initiation$
Vialsper
month
n
After mRDT
initiation#
Vialsper
month
n
Post-
intervention
vials
as a proportion
of
pre-
intervention
PP (95% CI)
Intervention health facilities
Hospital 1 495 4560 1326 0.29 3205 1503 0.47
Hospital 2 323 1500 307 0.20 5049 549 0.11
Hospital 3 335 3100 1608 0.52 1747 1048 0.60
Health
centre 1
329 3000 1890 0.63 830 272 0.33
Health
centre 2
209 1430 268 0.19 553 86 0.16
Health
centre 3
93 1540 360 0.23 177 92 0.52
Dispensary
1
43 650 25 0.04 59 26 0.44
Dispensary
2
101 770 202 0.26 245 85 0.35
Dispensary
3
210 4110 1947 0.47 303 111 0.37
Total of 9
HFŦ
0.32 (0.20 - 0.43) 0.37 (0.28 - 0.46)
Total of 6 matched intervention HFŦ 0.30 (0.15 - 0.46) 0.36 (0.24 - 0.48)
Control health facilities
Control 1 N.A 1900 1952 1.03 280 766 2.73
Control 2 N.A 3410 1353 0.40 209 151 0.72
Control 3 N.A 4180 2617 0.63 217 871 4.01
Total of 3 matched control HFŦ 0.68 (0.46 - 0.91) 2.49 (1.62 - 3.35)
£ One blister of ALU is needed for one anti-malarial course, whatever the age or weight of the patient, &Between 2 and 6 vials are used per anti-malarial course,
* observation period of only 3 months because ALu only introduced in Tanzania in January 2007, # observation period of 18 months, $ observation period of 15
months, Ŧ allowing for random-effect.
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95% CI 1.00-1.28). In general, the amounts of antibiotics
consumed by HF were very high: about 38% of newly
attending patients received an oral antibiotic after
mRDT implementation versus 40% before.
Impact of mRDT implementation on laboratory tests other
than malaria
The number of urine analysis and direct stool examina-
tion increased slightly after mRDT implementation (PP
ratios 1.18 and 1.23 respectively) in intervention HF. In
control HF, both type of investigations increased more
(PP ratios 1.66 and 1.74 respectively).
Cross-sectional surveys: before-and-after analysis
The before-and-after analysis was based on the repeated
cross-sectional observation of consultations before and
after intervention in nine intervention HF (Table 2). No
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facilities. Pre-intervention follow up times vary because ALu was only introduced in January 2007.
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patient refused to be observed. The proportions of chil-
dren less than five years, children 5 to 15 years and
adults were similar in the pre- and the post-intervention
surveys (52%, 14% and 34% versus 53%, 16% and 32%, p
= 0.3), while slightly more female patients were included
in the pre-intervention survey (60% versus 54%, p =
0.02).
Impact of mRDT implementation on anti-malarials
prescription
Consultation observations performed before and after
mRDT implementation revealed a decrease of 77%
(from 75% to 20%) in the total number of patients
receiving an anti-malarial treatment (Table 2). This
decrease (RR 0.23, 95% CI 0.20-0.26) was slightly more
pronounced in the subgroup of patients not complaining
of fever (RR 0.16) than in the group complaining of
fever (RR 0.25). This reduction was mainly due to a
drastic change in the adherence of clinicians to test
results. At the time of microscopy, 53% (95% CI 47-60)
of negative patients were treated with anti-malarials
while this proportion was only 7% (95% CI 4-11) after
the introduction of mRDTs.
Impact of mRDT implementation on malaria testing
The overall proportion of patients tested for malaria
increased by 26%, from 68% to 83%, RR 1.26 (95% CI
1.19-1.33) after mRDT initiation. This increase was
mainly seen in patients complaining of fever (from 71%
to 91%). In patients without fever, a high proportion
was tested after mRDT implementation (49% before ver-
sus 58% after, p = 0.06) despite training instructions to
test only patients with fever.
Impact of mRDT implementation on antibiotics prescription
The overall prescription of antibiotics increased after
mRDT initiation by 47%, from 49% to 72%, RR 1.47
(95% CI 1.37-1.59). This increase was slightly more
important in patients complaining of fever (RR 1.50)
than in those not complaining of fever (RR 1.38) and
was seen in malaria negative patients but not in positive
ones. As a result, the vast majority [78% (95% CI 75-
81)] of negative patients were treated with an antibiotic
after the introduction of mRDTs.
Impact of mRDT implementation on laboratory tests other
than malaria
mRDT implementation did not dramatically increase the
request for alternative laboratory tests by clinicians,
which remained generally low.
Convergence of results between the longitudinal and the
before-and-after evaluations
Although the variability between HF was high, there was
a strong intra-health facility convergence of the main
outcome result (reduction of anti-malarial use) between
the longitudinal routine data assessment and the
repeated cross-sectional before-and-after assessment
(Lin concordance-correlation coefficient: rc = 0.91)
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(Figure 4). This is a strong confirmation of the robust-
ness of the data.
Cross-sectional surveys: cluster randomized controlled
analysis
The contemporaneous, post-intervention cluster rando-
mized comparison of patient consultations was carried
out in six intervention versus three control HF (Table 3).
The proportions of children less than five years, children
5 to 15 years and adults were close in the intervention
and control groups (39%, 17% and 45% versus 47%, 18%
and 35%, p = 0.02), and so was the number of female
patients (46% versus 40%, p = 0.1). Outcome results at
baseline were similar in intervention and control HF (p >
0.05) (results not shown). The analysis presented below
includes mainly data from the post-intervention survey.
Impact of mRDT implementation on anti-malarials
prescription
There was a considerable difference between the two
groups in the proportion of patients that were
Table 2 Before-and-after analysis based on repeated cross-sectional surveys investigating the consultation process:
effect of mRDT implementation on the main outcomes.
Before mRDT
implementation
Total patients = 937
After mRDT
implementation
Total patients = 954
Risk ratio(accounting for
clustering)
n* % (95% CI) n* % (95% CI) Risk ratio (95% CI) p-value
Effect of mRDT implementation on anti-malarial treatment
Patients treated with anti-malarials
All patients 894 75% (72-78) 912 20% (17-22) 0.23 (0.20 - 0.26) < 0.001
Patients complaining of fever 755 81% (79-84) 682 24% (20-27) 0.25 (0.22 - 0.29) < 0.001
Patients not complaining of fever 139 42% (33-50) 230 7% (4-11) 0.16 (0.10 - 0.27) < 0.001
Effect of mRDT implementation on adherence to malaria test result
Patients treated with anti-malarials
Patients with a positive malaria test 370 99% (99-100) 126 99% (98-100) 1.00 (0.98 - 1.01) 0.8
Patients with a negative malaria test 215 53% (47-60) 628 7% (5-9) 0.09 (0.06 - 0.13) <0.001
Effect of mRDT implementation on selection for malaria testing
Patients tested for malaria
All patients 937 68% (65-71) 954 83% (81-85) 1.26 (1.19 - 1.33) <0.001
Patients complaining of fever 782 71% (68-74) 717 91% (89-93) 1.31 (1.25 - 1.36) <0.001
Patients not complaining of fever 155 49% (41-57) 237 58% (52-65) 1.21 (0.99 - 1.48) 0.06
Effect of mRDT implementation on antibiotic treatment
Patients treated with antibiotics
All patients 894 49% (46-53) 912 72% (69-75) 1.47 (1.37 - 1.59) <0.001
Patients complaining of fever 755 49% (45-52) 682 73% (69-76) 1.50 (1.38 - 1.63) <0.001
Patients not complaining of fever 139 52% (43-60) 230 71% (65-77) 1.38 (1.16 - 1.65) <0.001
Patients with a positive malaria test 370 37% (32-42) 126 35% (26-43) 0.91 (0.68 - 1.21) 0.5
Patients with a negative malaria test 215 54% (47-61) 628 78% (75-81) 1.45 (1.28 - 1.65) <0.001
Effect of mRDT implementation on other laboratory tests than malaria
Patient tested for urine infection 937 7% (6-9) 954 13% (11-15) 1.74 (1.31 - 2.31) <0.001
Patient tested for typhoid (Widal) 937 2% (1-2) 954 1% (1-2) 0.76 (0.36 - 1.63) 0.5
Patient tested for stool parasites 937 6% (5-8) 954 7% (6-9) 1.13 (0.81 - 1.59) 0.5
* numbers differ from total sample size because of the variables applying to different subpopulations of patients (and for drugs because a few patients who did
not come back from laboratory to get treatment).
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prescribed anti-malarials: 22% in intervention versus
60% in control HF (from a baseline in both of 79%) (RR
0.30, 0.14-0.70) (Table 3). The difference was more pro-
nounced in non-febrile than in febrile patients since
only 9% of non-febrile patients received an anti-malarial
in intervention HF compared to 38% in control HF (RR
0.23, 95% CI 0.10-0.55). The reasons for the low anti-
malarial prescription in intervention HF were multiple:
better selection of patients for malaria testing, better
specificity of mRDT compared to microscopy and better
adherence to mRDT result. On the other hand, in con-
trol HF the lower anti-malarial prescriptions in the
post-versus pre-intervention survey was mainly due to a
better trust in malaria test results (negative patients
treated with anti-malarials decreased from 43% to 25%),
even if it was still based on microscopy.
Differences between intervention and control HF regarding
antibiotic prescriptions
The proportion of patients that were prescribed antibio-
tics was higher in intervention HF than in controls: 71%
versus 53% respectively (RR = 1.34, 95% CI 1.08-1.70) -
from a baseline of 50 and 51%. There was, however, no
significant difference by category of patients (with/with-
out fever; with positive/negative result), which con-
firmed that the overall difference in antibiotic
prescription was almost only due to the higher number
of negative patients and not to a behavioural change of
clinicians.
Impact of mRDT implementation on laboratory tests other
than malaria
The proportions of patients tested for urine, stool or the
Widal test did not increase after mRDT implementation
in both the intervention and control HF (p > 0.05).
Discussion
The implementation of mRDTs for malaria in nine
health facilities in Dar es Salaam in near-programme
conditions led to a dramatic reduction in anti-malarials
consumption. This was confirmed in all three methods
of evaluation with two independent data sets: the
Table 3 Cluster randomized controlled analysis based on the post-intervention cross-sectional survey investigating the
consultation process: comparison between 6 intervention and 3 control health facilities
Interventionhealth facilities
N = 637
Controlhealth facilities
N = 330
Risk ratio(accounting for clustering)
n* % (95% CI) n* % (95% CI) Risk ratio (95% CI) p-value
Effect of mRDT implementation on anti-malarial treatment
Patients treated with anti-malarials:
All patients 618 22% (19-25) 318 60% (54-65) 0.30 (0.14 - 0.70) 0.007
Patients complaining of fever 473 26% (22-30) 253 65% (59-71) 0.31 (0.16 - 0.67) 0.004
Patients not complaining of fever 145 9% (4-14) 65 38% (26-51) 0.23 (0.10 - 0.55) 0.001
Effect of mRDT implementation on adherence to malaria test result
Patients treated with anti-malarials:
Patients with a positive malaria test 96 100% (100-100) 155 100% (100-100) 1 N.A
Patients with a negative malaria test 412 7% (5-10) 128 25% (17-33) 0.09 (0.01 - 0.79) 0.03
Effect of mRDT implementation on selection for malaria testing
Patients tested for malaria:
All patients 637 82% (79-85) 330 89% (86-92) 0.93 (0.86 - 1.04) 0.2
Patients complaining of fever 487 90% (88-93) 263 95% (93-98) 0.95 (0.91 - 0.99) 0.03
Patients not complaining of fever 150 57% (49-65) 67 64% (52-76) 0.91 (0.69 - 1.26) 0.5
Effect of mRDT implementation on antibiotic treatment
Patients treated with antibiotics:
All patients 618 71% (67-74) 318 53% (48-59) 1.34 (1.08 - 1.70) 0.006
Patients complaining of fever 473 71% (67-76) 253 52% (46-58) 1.44 (1.09 - 1.94) 0.008
Patients not complaining of fever 145 68% (61-76) 65 58% (46-71) 1.17 (0.94 - 1.49) 0.2
Patients with a positive malaria test 96 32% (23-42) 155 28% (21-36) 1.14 (0.77 - 1.66) 0.5
Patients with a negative malaria test 412 77% (73-81) 128 74% (67-82) 1.05 (0.91 - 1.26) 0.5
Effect of mRDT implementation on other laboratory tests than malaria
Patient tested for urine infection 637 9% (7-11) 330 11% (8-15) 0.73 (0.34 - 1.58) 0.4
Patient tested for typhoid (Widal) 637 2% (1-3) 330 8% (5-11) 0.29 (0.04 - 1.97) 0.2
Patient tested for stool parasites 637 7% (5-9) 330 5% (3-8) 1.27 (0.50 - 3.29) 0.6
* numbers differ from total sample size because of the variables applying to different subpopulations of patients (and for drugs because a few patients who did
not come back from laboratory to get treatment).
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longitudinal analysis of routine statistics (Post-over Pre-
intervention ratio of 0.32 for ALu and 0.37 for injectable
quinine), the before-and-after study based on pre- and
post-intervention surveys (Risk ratio 0.23 for the first-
line treatment and 0.35 for injectable quinine) and the
cluster randomized analysis comparing matched inter-
vention and control health facilities (Risk ratio 0.26 for
the first line treatment and 0.43 for injectable quinine)
(see Figure 5).
The high level of convergence of the results confirms
the robustness to the findings. The two main reasons
for this decrease were illuminated by the observations
of patient-provider interactions in the repeated cross
sectional surveys. Firstly, the higher accuracy of rou-
tine mRDTs compared to routine microscopy led to a
dramatic reduction in the number of positive patients.
Secondly, as health workers trusted mRDT results, the
proportion of test-negative patients treated with anti-
malarials dropped from 53% to 7%. The impact was
maintained up to the end of the observation period (18
months) and even increased after the initial four
months thanks to targeted programmatic actions in
poor-performing HF. In the control HF there was a
moderate decrease in ALu consumption (PP ratio
0.68), but a corresponding increase in quinine con-
sumption and in the number of patients diagnosed
with malaria.
The repeated cross sectional surveys showed that 1.49
mRDTs were needed to save one malaria treatment
course. This was, however, at the cost of an additional
0.41 antibiotic treatment courses. If clinicians had been
fully adherent to both patients selection for mRDT test-
ing and treatment upon mRDT result, only 1.22 mRDTs
would have been required. The post-intervention survey
took place just after the rainy season, when 18% of
patients complaining of fever were positive by mRDT. If
the malaria prevalence had been 5% (the lowest monthly
rate observed in Dar es Salaam), clinicians would have
needed 1.05 mRDTs per anti-malarial treatment saved.
From the longitudinal study, in which wastage of drugs
between the main store and the dispensing window was
important, it was found that 2.15 mRDTs were neces-
sary to save one ALu blister and half a vial of quinine.
These observations show clearly how circumstances
shape the effectiveness of mRDT implementation.
An interesting observation was the “contamination” of
the control HF with some of the key messages from the
training activities. This was mainly due to health work-
ers from intervention HF being transferred to control
HF during the study period. The message that the inci-
dence of malaria in Dar es Salaam was much lower than
commonly thought was clearly passed on to control HF.
This helped clinicians to withhold anti-malarials when
the result of microscopy was negative and presumably
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also the microscopists to refrain from giving so many
false positive results.
Routine statistics were useful in this case because of
the reasonable quality of registers in Dar es Salaam.
Besides giving a robust confirmation that clinicians’
behaviour changes took place, this gave for the first
time a unique measure of the amount of anti-malarial
drug that could be saved following mRDT implementa-
tion: 12,727 ALu blisters and 6,061 quinine vials per
month in nine HF, including the three district hospitals.
The analysis of these routine statistics also identified
another important source of drug wastage: the mishand-
ling of drug stocks that were either lost, diverted or got
expired between the main store and the patients. Initia-
tives aimed at reducing drug wastage should thus not
only target clinicians’ prescription behaviour but also
drug management more generally.
There are currently nine studies that looked at the
impact of mRDT on anti-malarial prescription or clini-
cians’ adherence to mRDT result. One Kenyan study
was inconclusive because adherence to test result was
already very high prior to any intervention [19]; two stu-
dies from Tanzania and Burkina Faso showed no effect
of mRDT at all [12,13]; three studies from Zanzibar
[20], Uganda [21] and Tanzania mainland [22] showed a
strong impact (RR 0.42 and 0.29 for anti-malarial pre-
scription and RR 0.29 for over-prescription respectively).
A Zambian survey, conducted one year after deployment
of mRDT at national scale, showed intermediate results
(RR 0.62 for negative patients treated with anti-malar-
ials), but was underpowered because of an unexpected
low number of patients tested for malaria [23]. A study
in Ghana found a moderate impact in facilities without
microscopy (RR 0.75 for anti-malarial prescription) and
no impact at all in facilities using microscopy previously
[14]. A recent study from Uganda showed a moderate
impact (RR 0.62 for anti-malarial prescription) due to a
significant number of patients still treated while negative
[24]. All these studies are very heterogeneous in terms
of setting, design and type of training and there are
probably several reasons for failure or success. These
studies were all different from the present one in several
ways: they took place in rather controlled conditions
(except the Zambian study), used consultation observa-
tions only, and were conducted shortly after the start of
mRDT implementation (with or without a baseline sur-
vey). In Zambia, the very first experience of mRDT use
in Africa outside South-Africa, the main problem was
probably the assumption that clinicians would act upon
mRDT result without problem [23]. By contrast, the
successful Ugandan study put a strong emphasis on
training and on giving straightforward messages [21].
The successful Zanzibar study used a weekly cross-over
design where nurses received a financial incentive to
participate in the study and adhere to specific instruc-
tions on mRDT [20]. The Tanzanian mainland study
was also successful although no direct incentive was
given, but a study staff member was physically on-site
during the entire study period and facilities were visited
frequently by the supervisory staff [22]. The reasons
given by the authors of the Tanzanian study showing no
impact was the insufficient training on mRDT given to
clinicians [12]. Another possible explanation for the low
impact of mRDT implementation found in this study, as
well as in the studies of Burkina Faso [13] and Ghana
[14] might be related to the study methodology: they all
used the patient as allocation/randomization unit and
not the health facility. However, introducing mRDT
requires an in-depth change of the provider’s diagnosis
and treatment concepts. This can only be achieved with
a supporting environment, which constantly and consis-
tently re-enforces the new approach. Such a change can-
not be expected when the same clinician is asked to
apply two different strategies to the patients s/he sees
during the same day. The only way to significantly
improve the outcome of RDT implementation is when
all professionals working in one health facility consis-
tently implement one strategy.
Based on the observations made during the study and
on the feed-back given by clinicians, it is postulated that
the major determinants for the positive results of the
present programme were the following: (1) the study
was presented to clinicians as the pilot phase of a
planned national deployment of mRDT; (2) one of the
main investigator of the study was the City Medical
Officer of Health, hence health workers did not consider
this study as an isolated research project but rather as
the new guidelines for malaria management in the city;
(3) the training and the evidence it provided was appre-
ciated by the target audience of health care profes-
sionals. For them, the evidence on the low malaria
prevalence in Dar es Salaam, on the bad quality of rou-
tine microscopy and on the excellent performance of
mRDT (from meta-analyses and data acquired locally)
was new and very relevant. They also had the possibility
to link this knowledge to their own reality with cases
studies. The health care workers also appreciated the
possibility to discuss the mutual mistrust between
laboratory staff and clinicians with regard to malaria
testing, and that they were presented a tool (the
mRDTs) to overcome this issue. Clear take-home mes-
sages were also given, avoiding ambiguous messages
[25]. It is likely that the present experience would be
reproducible in the context of a well-planned program-
matic deployment of mRDT in the public health system.
Indeed this programme included only a short training
(one-day), limited supervision (once quarterly) and
absence of financial incentives. With regard to the
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applicability of these results in other settings, we carried
out a similar study in a rural area of Tanzania (Kilo-
mbero/Ulanga Districts), although without a control
group [26]. The endemicity there was higher than in
Dar es Salaam. The impact on the overall consumption
of anti-malarials was, therefore, less (a two-fold
decrease) due to the much higher proportion of fever
cases associated with parasitaemia (39% instead of 8% in
Dar es Salaam). Interestingly, the adherence of clinicians
to the recommendation of not treating negative patients
was even higher in that remote setting (only 1% of nega-
tive patients received an anti-malarial drug), similarly to
what was observed recently with community health
workers using mRDT in Zambia [27].
Besides saving anti-malarial treatments, one important
aspect of RDT implementation is the selection of
patients for malaria testing. Patients presenting with a
wide range of medical condition were deliberately
included to explore clinicians’ behavior towards malaria
test requests. During the training, the necessity of test-
ing only patients complaining of fever was emphasized.
Unfortunately no impact was obtained on this outcome.
During the feed-back meeting organized after the end of
the study, clinicians stated that the pressure of patients
for testing (much more than treating) was high, in parti-
cular when coming for a check-up. Moreover, in con-
trast to treatment, there is no risk for the patient to be
tested.
The large-scale deployment of mRDT is of course
going beyond behaviour change alone. There are major
health system challenges, starting with the need to con-
siderably strengthen the capacity to order/purchase and
deliver goods (mRDT and drugs) in areas that have
always had poor coverage of health interventions [28].
The respective role of mRDT and/or microscopy needs
to be determined in different settings and different clini-
cal situations. Also, an effective quality assurance system
to support mRDT introduction needs to be established.
Some major improvements have been made to develop
a monitoring process to evaluate the performance of dif-
ferent brands and batches of mRDT in recent years [29].
Considerable efforts need still to be invested to ensure
appropriate use of mRDT in the field, with a focus on
the integrated management of childhood illness in the
community and the management of non-malaria fevers.
An increased use of broad-spectrum antibiotics in most
of mRDT negative cases has indeed been shown in the
present study (in the cross-sectional surveys but not in
the longitudinal study probably because the effect of
RDT diluted itself in the overall very large consumption
of antibiotics by HFs for all types of patients) as well as
in recent studies in Tanzania and Zanzibar [20,30]. A
significant increase in the indiscriminate use of antibio-
tics in sub-Saharan Africa is likely to add to the global
problem of antibiotic resistance and should be prevented
by all means [31].
Limitations of the study
The main limitation of the cluster randomized control
study is the low number of clusters (three). When the
study was designed, the priority was deliberately put on
the before-and-after component. Indeed, the high het-
erogeneity between HF makes them quite difficult to be
compared, even after matching on several criteria. Con-
tamination between intervention and control HF was
also a risk that in fact occurred during this study. Also
knowing the potential benefit of RDT, to convince more
health facilities to be in the control arm would have
been difficult. Knowing that the malaria transmission
would not have time to change drastically in a 2 year
period, the before-and-after analysis was thus considered
to be potentially more robust than the cluster rando-
mized control analysis.
Another limitation comes from the longitudinal study
in which the impact of mRDT on anti-malarials con-
sumption on the long term might have been underesti-
mated. Indeed the ALu decrease was less pronounced in
the first 4 months post mRDT initiation than in the fol-
lowing months. This was related to problems at the
start of the implementation - which could be solved.
Also the total number of attendances slightly increased
over time, while the data for tests and drugs were not
corrected by the total number of patients. The pre-inter-
vention period was very short for ALu (3 months),
which reduces the strength of the assessment. However,
the impact measured on the consumption of quinine
vials, which was based on a longer pre-intervention per-
iod (15 months), was quite similar to that of ALu.
Conclusions
When deployed appropriately (official support of the
new tool by senior health authorities, high quality train-
ing, regular routine supervision and monitoring after
implementation), mRDTs lead to a considerable saving
of oral and injectable anti-malarial drugs at all levels of
the health system, including in hospitals. mRDT also
prevent patients from misdiagnosis and adverse events
of unnecessary anti-malarial treatments. The potential of
anti-malarial saving through mRDT use could be maxi-
mized if other causes of drug wastage were tackled as
well, i.e. drug procurement mechanisms based on the
number of confirmed malaria patients, rigorous and
dynamic management of stocks, similar diagnostic and
treatment strategies in the private sector including phar-
macies and drug shops [32]. The downside of mRDT
implementation is the shift from anti-malarial wastage
to antibiotic wastage due to insufficient knowledge and
training on other causes of fever. Deployment of mRDT
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should therefore move hand in hand with strategies
aimed at reducing irrational use of antibiotics at outpati-
ent level, for example through updated IMCI decision
charts promoted by innovative approaches for teaching
and communication.
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